The DOI matches its Crossref record; the references it cites are not checked yet.
The machine learning life cycle and the cloud: implications for drug discovery
Open accessAbstract
Introduction: Artificial intelligence (AI) and machine learning (ML) are increasingly used in many aspects of drug discovery. Larger data sizes and methods such as Deep Neural Networks contribute to challenges in data management, the required software stack, and computational infrastructure. There is an increasing need in drug discovery to continuously re-train models and make them available in production environments.Areas covered: This article describes how cloud computing can aid the ML life cycle in drug discovery. The authors discuss opportunities with containerization and scientific workflows and introduce the concept of MLOps and describe how it can facilitate reproducible and robust ML modeling in drug discovery organizations. They also discuss ML on private, sensitive and regulated data.Expert opinion: Cloud computing offers a compelling suite of building blocks to sustain the ML life cycle integrated in iterative drug discovery. Containerization and platforms such as Kubernetes together with scientific workflows can enable reproducible and resilient analysis pipelines, and the elasticity and flexibility of cloud infrastructures enables scalable and efficient access to compute resources. Drug discovery commonly involves working with sensitive or private data, and cloud computing and federated learning can contribute toward enabling collaborative drug discovery within and between organizations.Abbreviations: AI = Artificial Intelligence; DL = Deep Learning; GPU = Graphics Processing Unit; IaaS = Infrastructure as a Service; K8S = Kubernetes; ML = Machine Learning; MLOps = Machine Learning and Operations; PaaS = Platform as a Service; QC = Quality Control; SaaS = Software as a Service
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“that require a strong governance [27], [32], [45]”
From Machine Learning Operations (MLOps): Overview, Definition, and Architecture (2023) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 55 · Cited by 67
Research works printed but not linked: 2
- Gudivada V, Apon A, Ding J. Data quality considerations for big data and machine learning: going beyond data cleaning and transformations. Int J Adv Software. 2017;10:1–20.
- 10.1038/s41592-020-01023-0 · DOI
Metadata
- Authors
- Spjuth, O., Frid, J., & Hellander, A.
- Affiliations
- Uppsala University (SE)
- Scaleout Systems AB
- Corresponding author
- Spjuth, Ola
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2021-05-31
- Volume
- 16
- Issue
- 9
- Pages
- 1071-1079
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W3165081806
- Cited by
- 67
- References
- 55
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 19 · 2023: 13 · 2022: 7 · 2021: 3
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Expert Opinion on Drug Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- FORMAS
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Decision Sciences › Information Systems and Management › Scientific Computing and Data Management
- Physical Sciences › Computer Science › Information Systems › Cloud Computing and Resource Management
- Keywords
- machine learning lifecycle, cloud computing, drug discovery, MLOps, containerization, Kubernetes, scientific workflows, reproducibility, model retraining, private data, sensitive data, federated learning, data management, IT infrastructure
- MeSH terms
- Cloud Computing, Machine Learning, Animals, Artificial Intelligence, Humans, Life Cycle Stages, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The machine learning life cycle and the cloud: implications for drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2021.1932812
- The paper
- Spjuth, O., Frid, J., & Hellander, A. (2021). The machine learning life cycle and the cloud: implications for drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2021.1932812
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.